PMID- 34104234
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1844-3117 (Electronic)
IS  - 1844-122X (Print)
IS  - 1844-122X (Linking)
VI  - 14
IP  - 2
DP  - 2021 Mar-Apr
TI  - Vitiligo and chronic autoimmune thyroiditis.
PG  - 127-130
LID - 10.25122/jml-2019-0134 [doi]
AB  - Vitiligo, the discoloration of the skin, has different autoimmune mechanisms 
      reflected by many biomarkers as shown by skin histology, staining for CD4 and CD8 
      T lymphocytes, chemokine ligand 9 or circulating cytokines such as interleukin 
      (IL)-1 beta, interferon (IFN)-gamma, transforming growth factor (TGF)-beta, 
      antibodies, markers of oxidative stress, chemokines, and others. In this 
      narrative review, we aim to overview vitiligo in relationship with chronic 
      autoimmune thyroiditis. Regarding vitiligo, more than 50 different genetic loci 
      have been associated with this disease, and the heritability is high. There is a 
      20% risk of an environmental connection which may also act as a trigger; 
      moreover, the association with human leukocyte antigen (HLA) expression is well 
      recognized. The specific lesions display CD8+ tissue-resident memory T cells as 
      continuous key activators of melanocytes. The association with chronic 
      thyroiditis is based on common autoimmune background and excessive reactive 
      oxygen species that destroy melanocytes and thyrocytes (oxidative stress 
      hypothesis) with thyroxine and melanin as target molecules, thus sharing a common 
      origin: tyrosine. Moreover, common epigenetic anomalies or mutations of the 
      Forkhead transcription factor D3 (FOXD3) have been described. Since vitiligo 
      affects up to 1-2% of the population worldwide and 34% of patients have positive 
      thyroid antibodies, apart from common autoimmunity background and oxidative 
      stress toxicity, the association is clinically relevant for different 
      practitioners.
CI  - (c)2021 JOURNAL of MEDICINE and LIFE.
FAU - Sandru, Florica
AU  - Sandru F
AD  - Department of Dermatology, Elias Emergency University Hospital, Bucharest, 
      Romania.
AD  - Department of Dermatology, Carol Davila University of Medicine and Pharmacy, 
      Bucharest, Romania.
FAU - Carsote, Mara
AU  - Carsote M
AD  - Department of Endocrinology, C. I. Parhon National Institute of Endocrinology, 
      Bucharest, Romania.
AD  - Department of Endocrinology, Carol Davila University of Medicine and Pharmacy, 
      Bucharest, Romania.
FAU - Albu, Simona Elena
AU  - Albu SE
AD  - Department of Obstetrics and Gynecology, Emergency University Hospital, 
      Bucharest, Romania.
AD  - Department of Obstetrics and Gynecology, Carol Davila University of Medicine and 
      Pharmacy, Bucharest, Romania.
FAU - Dumitrascu, Mihai Cristian
AU  - Dumitrascu MC
AD  - Department of Obstetrics and Gynecology, Emergency University Hospital, 
      Bucharest, Romania.
AD  - Department of Obstetrics and Gynecology, Carol Davila University of Medicine and 
      Pharmacy, Bucharest, Romania.
FAU - Valea, Ana
AU  - Valea A
AD  - Department of Endocrinology, Clinical County Hospital, Cluj-Napoca, Romania.
AD  - Department of Endocrinology, Iuliu Hatieganu University of Medicine and Pharmacy, 
      Cluj-Napoca, Romania.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Romania
TA  - J Med Life
JT  - Journal of medicine and life
JID - 101477617
RN  - Thyroiditis, Chronic
SB  - IM
MH  - Animals
MH  - Hashimoto Disease/complications
MH  - Humans
MH  - Thyroiditis/complications
MH  - Thyroiditis, Autoimmune/*complications
MH  - Vitiligo/*complications
PMC - PMC8169145
OTO - NOTNLM
OT  - ATG - anti-thyroglobulin antibodies
OT  - FOXD3 - forkhead transcription factor D3
OT  - IFN - interferon
OT  - IL - interleukin
OT  - JAK-STAT - Janus kinase-signal transducer and activator of transcription
OT  - ROS - reactive oxygen species
OT  - TGF - transforming growth factor
OT  - TPO - thyroid peroxidase antibodies
OT  - antibodies
OT  - thyroiditis
OT  - vitiligo
EDAT- 2021/06/10 06:00
MHDA- 2021/06/22 06:00
PMCR- 2021/05/01
CRDT- 2021/06/09 06:44
PHST- 2021/06/09 06:44 [entrez]
PHST- 2021/06/10 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2021/05/01 00:00 [pmc-release]
AID - JMedLife-14-127 [pii]
AID - 10.25122/jml-2019-0134 [doi]
PST - ppublish
SO  - J Med Life. 2021 Mar-Apr;14(2):127-130. doi: 10.25122/jml-2019-0134.